NASDAQ: SNYSanofi Stock
$48.31+0.46 (+0.96%)
Updated Jun 30, 2025
SNY Price
$48.31
Fair Value Price
$51.51
Market Cap
$122.04B
52 Week Low
$45.80
52 Week High
$60.12
P/E
20.89x
P/B
1.51x
P/S
2.62x
PEG
0.67x
Dividend Yield
4.58%
Revenue
$46.13B
Earnings
$5.79B
Gross Margin
70.2%
Operating Margin
17.7%
Profit Margin
12.6%
Debt to Equity
0.71
Operating Cash Flow
$9B
Beta
0.36
Next Earnings
Jul 23, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SNY Overview
Sanofi is a multinational pharmaceutical and healthcare company. The company provides specialty care products, including human monoclonal antibodies, products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, rare blood disorders, diabetes, and cardiovascular and established prescription products. It also has pharmaceutical products and vaccines in developmental stage. The company was founded in 1973 and is headquartered in Paris, France.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SNY's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
SNY
Ranked#14 of 18
Ranked#14 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $121.01 | A | |
| $152.75 | A | |
| $9.04 | B |
Be the first to know about important SNY news, forecast changes, insider trades & much more!
SNY News
Overview
Due Diligence Score
–
Industry Average (44)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SNY scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SNY ($48.31) is undervalued by 6.2% relative to our estimate of its Fair Value price of $51.51 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SNY ($48.31) is not significantly undervalued (6.2%) relative to our estimate of its Fair Value price of $51.51 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SNY ($48.31) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more SNY due diligence checks available for Premium users.
Valuation
SNY fair value
Fair Value of SNY stock based on Discounted Cash Flow (DCF)
Price
$48.31
Fair Value
$51.51
Undervalued by
6.20%
SNY ($48.31) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SNY ($48.31) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SNY ($48.31) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SNY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
20.89x
Industry
37.73x
Market
32.47x
SNY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SNY is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
SNY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.51x
Industry
5.91x
SNY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SNY price to earnings growth (PEG)
For valuing profitable companies with growth potential
SNY is good value based... subscribe to Premium to read more.
PEG Value Valuation
SNY's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
SNY's Earnings (EBIT) of $8.16B... subscribe to Premium to read more.
Interest Coverage Financials
SNY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$138.3B
Liabilities
$57.2B
Debt to equity
0.71
SNY's short-term assets ($44.36B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNY's short-term assets ($44.36B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SNY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
SNY's operating cash flow ($9.46B)... subscribe to Premium to read more.
Debt Coverage Financials
SNY vs General Drug Manufacturer Stocks
Sanofi Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.